

Supplementary Material

Clinical Benefits and Safety of Medical Cannabis Products: A

Narrative Review

Authors: Gérard Mick ^{1,2,3,4}, Pascal Douek⁵

Affiliations

¹ Pain Center, Voiron Hospital, CHU Grenoble-Alpes-Voiron, 38500 Grenoble, France

² CETD, Hôpital Neurologique Pierre Wertheimer, CHU de Lyon—Hospices Civils de Lyon (HCL), 69500 Bron, France

³ Health Systemic Process (P2S), Unit Research UR4129, University Claude Bernard Lyon 1, University of Lyon, 69008 Lyon, France

⁴ Équipe THEMAS, laboratoire TIMC, Université Grenoble Alpes, 38000 Grenoble, France

⁵ Société Déclic Attitude, 34200 Sete, France

Corresponding author

Gérard Mick, CHU Grenoble-Alpes-Voiron, Voiron, France

Email: GMick@chu-grenoble.fr

Contents

Supplementary Information.....	2
Search terms.....	2
Supplementary Table 1. Search terms.....	3

Supplementary Information.

Search terms

An electronic search of PubMed was performed between 11–13 March 2023 using MeSH terms and keywords using Boolean operators (AND, OR) to identify and retrieve articles spanning three areas of interest. 1) efficacy of cannabinoids in neuropathic pain, spasticity and cancer symptoms; 2) safety profile and 3) addictive potential of cannabinoids in all indications, and the comparative safety of medical and recreational cannabis (**Supplementary Table 1**). While no language restrictions were applied, we focused our search to those articles published within the past decade (from 2010 to 2023). Titles and abstracts were reviewed for relevance, and if so, the full article retrieved and reviewed. Reference lists of reviewed publications were also appraised for additional publications that may have been overlooked. Identified articles were supplemented by snowball sampling of relevant citations from the consulted papers (including a number of comprehensive, systematic reviews) which included forward snowballing with more recent papers identified in Google Scholar. Subsequent *ad hoc* searches, along with continued citation chasing and snowball sampling was used to remain up to date with emerging literature.

Supplementary Table 1. Search terms

1. Efficacy of cannabinoids in neuropathic pain, spasticity and cancer symptoms
("Cannabinoids"[Mesh] OR "Cannabis"[Mesh] OR "Medical Marijuana"[Mesh] OR phytocannabinoids) AND ((neuralgia OR spasticity OR (cancer AND nausea) OR (cancer and vomiting) OR (cancer and appetite) OR (cancer and anorexia) OR (cancer AND cachexia) OR ("neuropathic pain") OR (multiple sclerosis) OR (rheumat* AND pain AND France) OR fibromyalgia OR "rheumatoid arthritis" OR osteoarthritis)) AND ("practice guideline"[Publication Type] OR "guideline"[Publication Type] OR "metaanalysis"[Publication Type] OR "systematic review"[Publication Type] OR "consensus development conference"[Publication Type] OR "scoping review" OR "umbrella review")
2. Safety profile of cannabinoids
("Cannabinoids"[Mesh] OR "Cannabis"[Mesh] OR "Medical Marijuana"[Mesh] or phytocannabinoids) AND ("adverse effects" OR "Side effects" OR Safety OR Doping OR Driving OR Toxicity OR Interactions) AND ("meta analysis"[Publication Type] OR "clinical trial"[Publication Type] OR "systematic review"[Publication Type])
3. Addictive potential of cannabinoids
("Cannabinoids"[Mesh] OR "Cannabis"[Mesh] OR "Medical Marijuana"[Mesh] or phytocannabinoids) AND (Addict* OR Misuse OR Abuse OR Withdrawal OR craving) AND ("case reports"[publication type] OR "observational study"[publication type] OR "clinical trial"[Publication Type] OR "cohort study")